ZyVersa Therapeutics progressing with clinical trials, improving financial results, seeking additional financing.

From GlobeNewswire: 2024-08-09 16:40:00

ZyVersa Therapeutics, Inc. is progressing with Phase 2a clinical trials for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease and Inflammasome ASC Inhibitor IC 100 in obese patients with metabolic complications. The company has raised $0.8 million from investor warrants and is on track to achieve key development milestones by Q1-2025. Financial results show an improvement in net losses for the period ended June 30, 2024. Expenses for research and development have decreased, and ZyVersa plans to seek additional financing to fund its operations. ZyVersa remains focused on developing first-in-class drugs for inflammatory or kidney diseases with unmet medical needs.



Read more at GlobeNewswire:: ZyVersa Therapeutics Reports Second Quarter, 2024 Financial